A New Way to Rally the Immune System
For decades, researchers have searched for ways to harness the immune system against cancer without overwhelming the body with dangerous side effects. Now, scientists at Rockefeller University may have inched closer.
In a small but carefully designed phase 1 trial, a modified CD40 antibody drug—called 2141-V11—was injected directly into tumors of patients with advanced cancers. Of the 12 participants, six saw their tumors shrink, and two went into full remission. Importantly, the treatment appeared far safer than earlier versions of CD40 drugs, which in past studies triggered severe immune reactions.
The results, published in Cancer Cell, open a fresh chapter in immunotherapy research—one that bypasses some of the pitfalls of earlier strategies.
Why Cancer Needs New Approaches
Cancer remains one of the most pressing public health challenges. The National Institutes of Health estimates 2 million new cases and 600,000 deaths from cancer in the United States alone in 2025.
Although survival rates have improved thanks to early detection, surgery, chemotherapy, radiation, and immunotherapy, the need for new tools remains urgent. For cancers that spread beyond the initial site, treatment becomes exponentially harder.
That urgency is what drove the Rockefeller team to re-engineer the CD40 antibody, aiming to transform an idea once abandoned because of toxicity into a viable therapy.
How 2141-V11 Works
The CD40 receptor is a powerful “on-switch” for immune cells. When activated, it can rally the body’s defenses against tumors. But in previous trials, systemically administered CD40 agonists overstimulated the immune system, leading to dangerous inflammation and organ damage.
The researchers redesigned the drug to minimize toxicity and delivered it directly into tumors rather than through the bloodstream. Patients received injections every three weeks, with doses gradually increased.
Monitoring throughout the trial showed most side effects were mild—such as fever or injection-site reactions. No patient experienced the severe liver or platelet problems that had plagued earlier CD40 therapies.
Tumors Shrink, Remissions Appear
By the end of treatment, the results were striking for a first-in-human trial. Tumors shrank in half of the participants, and in two patients—one with melanoma, the other with breast cancer—cancer disappeared entirely, even in parts of the body that weren’t injected.
“This drug flips a key switch inside the tumor, turning immune cells into on-site training camps that teach T-cells how to fight,” explained Dr. Wael Harb, a hematologist and oncologist not involved in the study. “Those T-cells then circulate throughout the body to attack cancer elsewhere.”
What Comes Next
While the early data is promising, researchers caution against overinterpretation.
“Twelve patients are simply too few to draw broad conclusions,” said Dr. Juan Osorio, senior study author. Phase 2 trials are already underway in malignant gliomas, bladder cancer, and prostate cancer, with early results showing potential.
Still, Osorio stressed that this drug is unlikely to be a universal solution: “Not all patients respond, and we need to identify biomarkers that predict who will benefit.”
Researchers are also studying whether specific immune structures, called tertiary lymphoid structures (TLS), are key to long-term tumor control.
A Cautious but Hopeful Step
Experts say the findings mark an important moment in the evolving field of immunotherapy. By transforming tumors themselves into immune-activating hubs, 2141-V11 could represent a safer and more targeted way to unleash the body’s defenses.
If confirmed in larger studies, this approach may give oncologists a new option—one that’s not only more effective but also better tolerated than many existing treatments.
